Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21850104 | 0.83 | RECQL (0.31) | DPP4 | |
| SCHEMBL24847195 | 0.81 | PIK3CD (0.41) | PIK3CD | |
| SCHEMBL23979216 | 0.81 | — | — | |
| SCHEMBL25089408 | 0.81 | MLYCD (0.30) | — | |
| SCHEMBL22305055 | 0.78 | PIK3CD (0.31) | PIK3CD | |
| SCHEMBL15033278 | 0.76 | TP53BP1 (0.33) | POLB | |
| SCHEMBL22306097 | 0.75 | — | — | |
| SCHEMBL22952338 | 0.74 | — | — | |
| SCHEMBL13576184 | 0.73 | TP53BP1 (0.38) | POLB | |
| SCHEMBL17281866 | 0.73 | ALDH1A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018189-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-11793881-B2 | Polyethylene glycol conjugate medicament, preparation method therefor and use thereof | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2023-10-24 | — | — | US | disclosed |
| US-20230065463-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-20220125959-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AS DIAGNOSTIC AND RADIONUCLIDE THERAPEUTIC AGENTS | FIVE ELEVEN PHARMA INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-08-19 | — | — | US | disclosed |
| US-20210171564-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Cellix Bio Provate Limited (IN) | 2021-06-10 | — | — | US | disclosed |
| US-20210078983-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Cellix Bio Provate Limited (IN) | 2021-03-18 | — | — | US | disclosed |
| US-10858349-B2 | Compositions and methods for the treatment of cancer | CELLIX BIO PRIVATE LIMITED (IN) | 2020-12-08 | — | — | US | disclosed |
| US-20190292171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | CELLIX BIO PRIVATE LIMITED (IN) | 2019-09-26 | — | — | US | disclosed |
| WO-2018098269-A2 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20140323402-A1 | Protein Carrier-Linked Prodrugs | Ascendis Phama A/S (DK) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | DPP4 287/4885POLB 4628/4885DPP8 220/4885 |
| US-20240018189-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | DPP4 841/4885POLB 4339/4885DPP8 863/4885 |
| US-20210078983-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | SI, HBG2, HBG1 | DPP4 2714/4885POLB 1371/4885DPP8 4230/4885 |
| US-20190292171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | SI, HBG2, HBG1 | DPP4 2714/4885POLB 1371/4885DPP8 4230/4885 |
| US-11793881-B2 | Polyethylene glycol conjugate medicament, preparation method therefor and use thereof | SLC10A1, SLC10A2, NOTUM | DPP4 1642/4885POLB 3615/4885DPP8 711/4885 |
| US-20230065463-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | DPP4 3672/4885POLB 86/4885DPP8 3942/4885 |
| US-10858349-B2 | Compositions and methods for the treatment of cancer | SI, HBG2, HBG1 | DPP4 2714/4885POLB 1371/4885DPP8 4230/4885 |
| US-20140323402-A1 | Protein Carrier-Linked Prodrugs | SLC6A7, PRAP1, PELP1 | DPP4 1477/4885POLB 4278/4885DPP8 958/4885 |
| US-20220125959-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AS DIAGNOSTIC AND RADIONUCLIDE THERAPEUTIC AGENTS | KLK3, FOLH1, PSMA1 | DPP4 1437/4885POLB 2113/4885DPP8 345/4885 |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | SMARCC1, SMARCC2, SMARCA2 | DPP4 3941/4885POLB 55/4885DPP8 4460/4885 |
| US-20210171564-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | POLRMT, POLN, POLQ | DPP4 3971/4885POLB 7/4885DPP8 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.